• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

来自 ReIMAGINE 前列腺癌风险研究的最新进展（NCT04060589）：这是一项前瞻性队列研究，纳入了疑似前列腺癌并被转至基于磁共振成像的诊断途径的男性，他们捐赠了组织、血液和尿液以进行生物标志物分析。

An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses.

机构信息

UCL Division of Targeted Intervention, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Imperial Urology, Imperial College Healthcare NHS Trust, London, UK.

出版信息

Eur Urol. 2021 Oct;80(4):398-399. doi: 10.1016/j.eururo.2021.06.011. Epub 2021 Jul 1.

DOI:10.1016/j.eururo.2021.06.011
PMID:34218972
Abstract

ReIMAGINE represents the first efforts to define prostate cancer risk using the full spectrum of emerging diagnostics (both commercial and academic). The outputs will provide image-based data sets that will replace, or adjust, historical and flawed risk calculators.

摘要

ReIMAGINE 代表了首次利用新兴诊断技术（包括商业和学术）全面定义前列腺癌风险的努力。其结果将提供基于图像的数据集，以取代或调整有缺陷的历史风险计算器。

相似文献

1
An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses.来自 ReIMAGINE 前列腺癌风险研究的最新进展（NCT04060589）：这是一项前瞻性队列研究，纳入了疑似前列腺癌并被转至基于磁共振成像的诊断途径的男性，他们捐赠了组织、血液和尿液以进行生物标志物分析。
Eur Urol. 2021 Oct;80(4):398-399. doi: 10.1016/j.eururo.2021.06.011. Epub 2021 Jul 1.
2
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.ReIMAGINE 前列腺癌风险研究方案：一项前瞻性队列研究，纳入疑似前列腺癌并接受 MRI 为基础的诊断途径的男性，对其进行组织、血液和尿液的生物标志物分析。
PLoS One. 2022 Feb 24;17(2):e0259672. doi: 10.1371/journal.pone.0259672. eCollection 2022.
3
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.基于斯德哥尔摩 3 项血液检测和多参数磁共振成像的前列腺癌诊断。
Eur Urol. 2018 Dec;74(6):722-728. doi: 10.1016/j.eururo.2018.06.022. Epub 2018 Jul 9.
4
Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.多参数磁共振成像预测高级别前列腺癌：改善鹿特丹欧洲前列腺癌筛查风险计算器研究的风险预测。
Eur Urol. 2019 Feb;75(2):310-318. doi: 10.1016/j.eururo.2018.07.031. Epub 2018 Aug 3.
5
Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?PRECISION 试验活检策略在当代磁共振成像靶向活检队列中的应用-有多少临床显著前列腺癌被遗漏？
J Urol. 2021 Mar;205(3):740-747. doi: 10.1097/JU.0000000000001406. Epub 2020 Oct 7.
6
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.经直肠超声引导前列腺活检与多参数前列腺磁共振成像引导活检在前列腺特异性抗原升高的初次活检男性中的头对头比较：一项大型前瞻性多中心临床研究。
Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.
7
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.多参数 MRI 提高经直肠超声引导前列腺活检单独诊断前列腺癌的检出率：PROMIS 研究。
Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.
8
Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.在未经活检的男性中，双参数磁共振成像对前列腺癌诊断准确性的评估：前列腺癌检测的双参数 MRI（BIDOC）研究。
JAMA Netw Open. 2018 Jun 1;1(2):e180219. doi: 10.1001/jamanetworkopen.2018.0219.
9
Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.前瞻性研究比较了经直肠超声引导活检与磁共振（MR）成像引导活检在无既往前列腺活检史男性中的前列腺癌检出率。
Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14.
10
Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer.低可疑度多参数前列腺磁共振成像或良性磁共振成像引导活检诊断前列腺癌的临床转归。
J Urol. 2017 Aug;198(2):310-315. doi: 10.1016/j.juro.2017.02.073. Epub 2017 Feb 21.

引用本文的文献

1
The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE).RECONCILE 研究方案：利用基于影像的早期前列腺癌风险分层来区分进展者和非进展者（RECONCILE）。
PLoS One. 2024 Oct 17;19(10):e0295994. doi: 10.1371/journal.pone.0295994. eCollection 2024.
2
The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer.重新构想多模式仓库：利用人工智能对前列腺癌进行准确的风险分层。
Front Artif Intell. 2021 Nov 16;4:769582. doi: 10.3389/frai.2021.769582. eCollection 2021.